CN117721204A - ceRNA regulatory mechanism of circ0104727 and application thereof in glioma - Google Patents
ceRNA regulatory mechanism of circ0104727 and application thereof in glioma Download PDFInfo
- Publication number
- CN117721204A CN117721204A CN202311801007.9A CN202311801007A CN117721204A CN 117721204 A CN117721204 A CN 117721204A CN 202311801007 A CN202311801007 A CN 202311801007A CN 117721204 A CN117721204 A CN 117721204A
- Authority
- CN
- China
- Prior art keywords
- glioma
- hsa
- circ
- glioblastoma
- circsh3gl3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010018338 Glioma Diseases 0.000 title claims abstract description 73
- 208000032612 Glial tumor Diseases 0.000 title claims abstract description 70
- 108091026815 Competing endogenous RNA (CeRNA) Proteins 0.000 title claims abstract 3
- 230000008844 regulatory mechanism Effects 0.000 title abstract description 4
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 claims abstract description 32
- 101700026522 SMAD7 Proteins 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000005764 inhibitory process Effects 0.000 claims abstract description 8
- 238000004393 prognosis Methods 0.000 claims abstract description 8
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 claims abstract description 6
- 230000009137 competitive binding Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 5
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 claims abstract 3
- 230000014509 gene expression Effects 0.000 claims description 53
- 208000005017 glioblastoma Diseases 0.000 claims description 49
- 210000004027 cell Anatomy 0.000 claims description 43
- 108091062762 miR-21 stem-loop Proteins 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 31
- 230000001105 regulatory effect Effects 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 206010003571 Astrocytoma Diseases 0.000 claims description 18
- 102000015735 Beta-catenin Human genes 0.000 claims description 18
- 108060000903 Beta-catenin Proteins 0.000 claims description 18
- 238000001514 detection method Methods 0.000 claims description 14
- 230000019491 signal transduction Effects 0.000 claims description 13
- 108091070501 miRNA Proteins 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 201000010133 Oligodendroglioma Diseases 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 230000007730 Akt signaling Effects 0.000 claims description 7
- 208000030173 low grade glioma Diseases 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 208000029824 high grade glioma Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 201000011614 malignant glioma Diseases 0.000 claims description 6
- 230000003990 molecular pathway Effects 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 239000013603 viral vector Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002679 microRNA Substances 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 230000003321 amplification Effects 0.000 claims description 4
- 238000009396 hybridization Methods 0.000 claims description 4
- 238000007901 in situ hybridization Methods 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000002539 nanocarrier Substances 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 230000004709 cell invasion Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000007884 disintegrant Substances 0.000 claims description 3
- 210000001808 exosome Anatomy 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 238000012165 high-throughput sequencing Methods 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 150000002632 lipids Chemical class 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 238000000018 DNA microarray Methods 0.000 claims description 2
- 238000002105 Southern blotting Methods 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000006249 magnetic particle Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000040430 polynucleotide Human genes 0.000 claims description 2
- 108091033319 polynucleotide Proteins 0.000 claims description 2
- 239000002157 polynucleotide Substances 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 102000049873 Smad7 Human genes 0.000 description 27
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 21
- 108060001084 Luciferase Proteins 0.000 description 19
- 239000005089 Luciferase Substances 0.000 description 19
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 102000013814 Wnt Human genes 0.000 description 13
- -1 i.e. Proteins 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000011529 RT qPCR Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 8
- 108091007960 PI3Ks Proteins 0.000 description 8
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 101000688572 Homo sapiens Endophilin-A3 Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 5
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 5
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 5
- 230000002860 competitive effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 102100027309 Cyclic AMP-responsive element-binding protein 5 Human genes 0.000 description 4
- 102100024240 Endophilin-A3 Human genes 0.000 description 4
- 102100028929 Formin-1 Human genes 0.000 description 4
- 108091092584 GDNA Proteins 0.000 description 4
- 101000726193 Homo sapiens Cyclic AMP-responsive element-binding protein 5 Proteins 0.000 description 4
- 101001059390 Homo sapiens Formin-1 Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 229920002477 rna polymer Polymers 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000003827 upregulation Effects 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 108010092160 Dactinomycin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 3
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 3
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 102100023489 Transcription factor 4 Human genes 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000003468 luciferase reporter gene assay Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004960 subcellular localization Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108091028075 Circular RNA Proteins 0.000 description 2
- 102100039216 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000612655 Homo sapiens 26S proteasome non-ATPase regulatory subunit 1 Proteins 0.000 description 2
- 101000670093 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 101150110212 SH3GL3 gene Proteins 0.000 description 2
- 108700031279 Smad7 Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 2
- 206010066901 Treatment failure Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000007622 bioinformatic analysis Methods 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101150092476 ABCA1 gene Proteins 0.000 description 1
- 102000055510 ATP Binding Cassette Transporter 1 Human genes 0.000 description 1
- 108700005241 ATP Binding Cassette Transporter 1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
- 101000745252 Homo sapiens Plasma membrane ascorbate-dependent reductase CYBRD1 Proteins 0.000 description 1
- 101000611943 Homo sapiens Programmed cell death protein 4 Proteins 0.000 description 1
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
- 101000744536 Homo sapiens Ras-related protein Rab-27B Proteins 0.000 description 1
- 101000654697 Homo sapiens Semaphorin-5A Proteins 0.000 description 1
- 101000664599 Homo sapiens Tripartite motif-containing protein 2 Proteins 0.000 description 1
- 108091069006 Homo sapiens miR-125b-1 stem-loop Proteins 0.000 description 1
- 108091068998 Homo sapiens miR-191 stem-loop Proteins 0.000 description 1
- 108091064270 Homo sapiens miR-4787 stem-loop Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 108700005081 Overlapping Genes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102100039902 Plasma membrane ascorbate-dependent reductase CYBRD1 Human genes 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100039765 Ras-related protein Rab-27B Human genes 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 102100032782 Semaphorin-5A Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 102100038799 Tripartite motif-containing protein 2 Human genes 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000007983 brain glioma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000007711 cytoplasmic localization Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000010185 immunofluorescence analysis Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108091028606 miR-1 stem-loop Proteins 0.000 description 1
- 108091044592 miR-1-1 stem-loop Proteins 0.000 description 1
- 108091045542 miR-1-2 stem-loop Proteins 0.000 description 1
- 108091047831 miR-1-3 stem-loop Proteins 0.000 description 1
- 108091031494 miR-1-4 stem-loop Proteins 0.000 description 1
- 108091064825 miR-181c stem-loop Proteins 0.000 description 1
- 108091044400 miR-181c-1 stem-loop Proteins 0.000 description 1
- 108091048818 miR-181c-2 stem-loop Proteins 0.000 description 1
- 108091032779 miR-181c-3 stem-loop Proteins 0.000 description 1
- 108091090051 miR-615 stem-loop Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 102200082402 rs751610198 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- UAEJRRZPRZCUBE-UHFFFAOYSA-N trimethoxyalumane Chemical compound [Al+3].[O-]C.[O-]C.[O-]C UAEJRRZPRZCUBE-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of biological medicine, and particularly relates to a cerRNA regulation mechanism of circ0104727 and application thereof in glioma. The circ0104727 is taken as the ceRNA to regulate the occurrence of glioma through competitive binding of miRNA-21-5p, and eliminates the inhibition effect of miRNA-21-5p on TIMP3/SMAD 7. More specifically, the invention also provides application of circ0104727 in glioma diagnosis, classification, prognosis and treatment.
Description
Technical Field
The invention belongs to the field of biological medicine, and particularly relates to a cerRNA regulation mechanism of circ0104727 and application thereof in glioma.
Background
Circular RNA (circRNA) as a star molecule studied in recent years can adsorb miRNAs via a sponge to regulate the expression of a downstream target gene, and this mechanism is called competitive endogenous RNA (competitive endogenous RNA, ceRNA) theory. The competitive endogenous ribonucleic acid (ceRNA) hypothesis is a novel posttranscriptional regulation pattern of genes, i.e., messenger RNAs (mrnas) encoding proteins, long-chain non-coding RNAs (lncrnas), pseudogene transcripts, circular ribonucleic acids (circrnas), etc., can be regulated by binding microribonucleic acids (mirnas) to the expression of their target genes. The ceRNA is a supplement to the regulatory action of traditional micrornas (mirnas) and messenger RNAs (mrnas), and it has been found that a variety of RNA molecules can interact to form a ceRNA regulatory network to perform a biological function of post-transcriptional regulation, and play an important role in maintaining a normal physiological state and regulating the occurrence and development of diseases. The ceRNA network provides important scientific research value for comprehensively understanding the heterogeneity and molecular generation mechanism of glioma.
Gliomas are the most common primary tumor in the brain and spinal cord and remain incurable until now. Different genetic and non-genetic effects determine tumor biology and clinical processes. In 2007, the world health organization (World Health Organization, WHO) classified central nervous system tumors into 4 classes WHO i through iv. Among them, one type of brain glioma that is highly heterogeneous and most malignant is glioblastoma multiforme, glioblastoma (glioblastoma multiforme, GBM), whose median survival in patients is currently only about 15 months, even if actively co-administered.
Disclosure of Invention
Aiming at the technical problems faced at present, the invention screens differentially expressed circRNAs through glioblastoma (glioblastoma multiforme, GBM) gene chips, determines that the circSH3GL3 (hsa_circ_ 0104727) with remarkably low expression in glioma is taken as an entry point, and finally provides a novel mechanism that the circSH3GL3 competitively combines miR-21-5p to play a cerRNA role by combining RNA pull down, protein mass spectrometry and miRNA and mRNA sequencing on the basis of preliminary determination of the cancer suppressor gene role, wherein the circSH3GL3 eliminates the inhibition effect of miR-21-5p on downstream target genes TIMP3 and SMAD7, and plays an important role in glioma by respectively inhibiting PI3K/AKT and wnt/beta-catenin signal paths through TIMP3 and SMAD7 functional activation.
According to the results, a new strategy for combined treatment of glioma based on the circRNA and the signal path molecular inhibitor can be established, and a theoretical basis and an experimental basis are provided for developing and excavating tumor drug action targets.
Specifically, the invention provides the following technical scheme:
in a first aspect, the invention provides the use of hsa_circ_0104727 for modulating glioma development.
More specifically, the hsa_circ_0104727 as ceRNA modulates glioma occurrence by competitive binding to miRNA-21-5 p.
The term "ceRNA", i.e., competitive endogenous ribonucleic acid (competing endogenous RNA), as used herein, refers to protein-encoding messenger RNAs (mRNA), long-chain non-coding RNAs (lncRNA), pseudogene transcripts, circular ribonucleic acids (circRNA), and the like, which are regulated by binding microribonucleic acids (miRNA) to their target gene expression.
Preferably, the glioma comprises a WHO grade 1-4, wherein a WHO grade 1-2 may be referred to as a low grade glioma, e.g., an oligodendroglioma, an astrocytoma; WHO 3-4 may be referred to as high grade glioma, e.g., degenerative astrocytoma, glioblastoma.
In another aspect, the invention provides the use of a miRNA-circRNA-TIMP3 or miRNA-circRNA-SMAD7 regulatory module in modulating glioma development, or,
the invention provides an application of miRNA-circRNA-TIMP3 or miRNA-circRNA-SMAD7 regulating module in preparing a product for regulating glioma,
the circRNA is hsa_circ_0104727 and the miRNA is miR-21-5p.
Preferably, the glioma comprises a WHO grade 1-4, wherein a WHO grade 1-2 may be referred to as a low grade glioma, e.g., an oligodendroglioma, an astrocytoma; WHO 3-4 may be referred to as high grade glioma, e.g., degenerative astrocytoma, glioblastoma.
Preferably, the circRNA abrogates TIMP3/SMAD7 inhibition by miRNA.
More preferably, the TIMP3 inhibits the PI3K/AKT signaling pathway.
More preferably, the SMAD7 inhibits the Wnt/β -catenin signaling pathway.
Preferably, the PI3K/AKT signaling pathway and Wnt/β -catenin signaling pathway are important targets for glioma development.
In another aspect, the invention provides the use of a reagent for detecting hsa_circ_0104727 expression level in the preparation of a product having any one of the following functions:
1) Diagnosing glioblastoma, and diagnosing the glioblastoma,
2) The glioma is classified into a grade and a grade,
3) Prognosis of glioma patients is predicted.
Preferably, the glioblastoma is one of gliomas.
Preferably, the grading is to identify the glioma patient as a low grade glioma or a high grade glioma.
Preferably, the glioma comprises a WHO grade 1-4, wherein a WHO grade 1-2 may be referred to as a low grade glioma, e.g., an oligodendroglioma, an astrocytoma; WHO 3-4 may be referred to as high grade glioma, e.g., degenerative astrocytoma, glioblastoma.
Preferably, the reagent comprises a reagent used in detecting hsa_circ_0104727 expression level in the following method: detection methods based on PCR principle, southern hybridization methods, northern hybridization methods, dot hybridization methods, fluorescence in situ hybridization methods, DNA microarray methods, ASO methods, high throughput sequencing platform methods.
Specifically, the detection method based on the PCR principle comprises variable temperature amplification and constant temperature amplification.
In particular, the reagent may be a primer pair, probe or antisense nucleotide that specifically binds to hsa_circ_0104727.
Further, the reagent further comprises a detectable label.
Further, the detectable label includes a radioisotope, a nucleotide chromophore, an enzyme, a substrate, a fluorescent molecule, a chemiluminescent moiety, a magnetic particle, a bioluminescent moiety.
In another aspect, the invention provides a composition for treating glioma, comprising any one or more of the following:
1) hsa_circ_0104727 and/or hsa_circ_0104727 precursors,
2) A polynucleotide which is transcribed to form hsa_circ_0104727,
3) A delivery vehicle comprising 1) or 2) thereon,
4) An agent for promoting hsa_circ_0104727 expression,
5) A molecular pathway inhibitor, said molecular pathway comprising a PI3K/AKT signaling pathway and a Wnt/β -catenin signaling pathway.
Preferably, the composition contains a molecular pathway inhibitor.
Preferably, the delivery vehicle comprises an exosome, a viral vector, a lipid nanoparticle (lipid nanoparticle, LNP), a polymeric nanocarrier, an inorganic nanocarrier, or a protein carrier.
Preferably, the viral vector comprises a lentiviral vector, an adenoviral vector, an adeno-associated viral vector.
Preferably, a pharmaceutically acceptable solid/liquid excipient is also included in the composition.
Preferably, the pharmaceutically acceptable solid/liquid excipients include binders, fillers, lubricants and disintegrants.
The dosage form and mode of administration of the composition of the present invention are not particularly limited. Representative modes of administration include, but are not limited to: oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) injection, and topical administration.
In a specific embodiment, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is admixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following ingredients: (a) Fillers or compatibilizers, for example, starch, lactose, sucrose, glucose, mannitol and silicic acid; (b) Binders, for example, hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and acacia; (c) humectants, e.g., glycerin; (d) Disintegrants, for example, agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) a slow solvent, such as paraffin; (f) an absorption accelerator, e.g., a quaternary amine compound; (g) Wetting agents, such as cetyl alcohol and glycerol monostearate; (h) an adsorbent, for example, kaolin; and (i) a lubricant, for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or mixtures thereof. In capsules, tablets and pills, the dosage forms may also comprise buffering agents. Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other materials well known in the art. They may contain opacifying agents and the release of the active compound or compounds in such compositions may be released in a delayed manner in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and waxes. The active compound may also be in the form of microcapsules with one or more of the above excipients, if desired.
In a specific embodiment, the liquid dosage form for oral administration comprises a pharmaceutically acceptable emulsion, solution, suspension, syrup or tincture. In addition to the active compound, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, propylene glycol, 1, 3-butylene glycol, dimethylformamide and oils, in particular, cottonseed, groundnut, corn germ, olive, castor and sesame oils or mixtures of these substances. In addition to these inert diluents, the compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. Such as suspensions, may contain suspending agents as, for example, particularly ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or mixtures of these substances.
In a particular embodiment, a composition for parenteral injection may comprise a physiologically acceptable sterile aqueous or anhydrous solution, dispersion, suspension or emulsion, and a sterile powder for reconstitution into a sterile injectable solution or dispersion. Suitable aqueous or nonaqueous carriers, diluents, solvents or excipients include water, ethanol, polyols and suitable mixtures thereof.
In a specific embodiment, the dosage forms for topical administration include ointments, powders, patches, sprays and inhalants. Is prepared by mixing the active ingredient under aseptic condition with pharmaceutically acceptable carrier and any preservative, buffer or propellant as required.
Preferably, the dosage form of the composition comprises a capsule, tablet, pill, powder, granule, emulsion, solution, suspension, syrup or tincture.
In another aspect, the invention provides the use of the above composition in the manufacture of a medicament for the treatment of glioma.
Preferably, the glioma comprises a WHO 1-4 grade glioma.
Preferably, the glioma comprises an oligodendroglioma, an astrocytoma, a modified astrocytoma or a glioblastoma.
Preferably, the glioma is glioblastoma.
In another aspect, the invention provides a method of diagnosing glioblastoma, typing glioma, or predicting a prognosis in a patient with glioma, the method comprising detecting the expression level of hsa_circ_0104727 in a sample from a subject.
Preferably, the sample comprises: peripheral blood, tissue, blood, serum, plasma, urine, saliva, semen, milk, cerebrospinal fluid, tears, sputum, mucous, lymph, cytosol, ascites, pleural effusion, amniotic fluid, bladder irrigation fluid, and bronchoalveolar lavage fluid.
Preferably, the sample is tissue.
In another aspect, the invention provides a method of inhibiting proliferation and invasion of glioma cells, the method comprising increasing the expression level of hsa_circ_0104727 in a target cell.
Preferably, the method is non-therapeutic.
Preferably, the method is performed in vitro.
Preferably, the target cell is a glioma cell, including glioblastoma cells.
Specifically, in the specific embodiment of the invention, an overexpression experiment is performed on a LN229 glioblastoma cell line with low hsa_circ_0104727 expression and a U251 glioblastoma cell line as examples, and it is proved that the proliferation and invasion capacity of cells are inhibited after the hsa_circ_0104727 is overexpressed, and in addition, a knockout experiment is performed on a U87 (also called ATCC HTB-14) glioblastoma cell line with high hsa_circ_0104727 expression and the opposite result is obtained.
In another aspect, the invention provides a method of treating glioma comprising administering to a patient the aforementioned composition or hsa_circ_0104727.
Specifically, the administration mode of the administration is not particularly limited. Representative modes of administration include, but are not limited to: oral, intratumoral, rectal, parenteral (intravenous, intramuscular or subcutaneous) injection, and topical administration.
Specifically, glioblastoma cells are included in the glioma.
In another aspect, the present invention provides a system having a judging device for giving any one of the following results by the expression level of hsa_circ_ 0104727:
1) Whether the subject has glioblastoma,
2) Glioma typing of the subject,
3) Prognosis of glioma patients.
The prognosis index of the present invention includes objective remission rate (Objective Response Rate, ORR), overall survival rate (Overall survival rate, overall survival, OS), progression-free survival (PFS), time To Progression (TTP), disease-free survival (DFS), treatment failure time (time to treatment failure, TTF), response Rate (RR), complete Response (CR), partial Response (PR).
Drawings
FIG. 1 is a cluster map of the detection of the expression profile of circRNA between clinical GBM specimens and corresponding paired adjacent normal tissues.
FIG. 2 is a graph of qRT-PCR detection results of circRNA0071539, circRNA0104727 and circRNA 0104722.
FIG. 3 is a comparison of the expression levels of circSH3GL3 in different cases.
FIG. 4 is a graph showing the result of electrophoresis of amplified linear genes SH3GL3 and circSH3GL3.
FIG. 5 is a graph of Sanger sequencing results.
FIG. 6 is a graph showing the results of RNase enzyme digestion of linear mRNA and circSH3GL3.
FIG. 7 is a graph showing the results of subcellular localization of circSH3GL3.
FIG. 8 is a graph of the detection results of over-expression and knock-down efficiency.
FIG. 9 is a graph showing the results of CCK8 experiments.
Fig. 10 is a graph showing the results of Edu experiments.
FIG. 11 is a graph showing the results of a Transwell experiment.
FIG. 12 is a cluster map of mRNA sequencing enrichment.
FIG. 13 is a plasmid vector map of the luciferase reporter plasmid vector pmirGLO.
FIG. 14 is a graph showing the results of luciferase activity assay.
FIG. 15 is a graph of the results of RNA pull Down experiments with biomarker miR-21-5p.
FIG. 16 is a graph of experimental results of LN229 and U87 cell proliferation assays transfected with miR21-5pmimic alone and with cotransfected circSH3GL3.
FIG. 17 is a flowchart showing the selection of differentially expressed genes from U87-circSH3GL3 cells compared to U87-vector cells.
FIG. 18 is a graph of qRT-PCR results for TIMP3, SMAD7, FMN1 and CREB5 mRNA.
FIG. 19 is a schematic representation of a miR-21-5p seed sequence for TIMP3 matching the SMAD 7' UTR.
FIG. 20 is a graph showing the results of Western blot experiments.
FIG. 21 is a graph showing the results of detection of a luciferase reporter gene.
FIG. 22 is a graph showing the results of Western blot detection of the amounts of PI3K, P-PI3K, AKT1, P-AKT, caspase3 protein expression.
FIG. 23 is a graph showing the results of TOP/FOP luciferase reporter experiments.
FIG. 24 is a graph showing the results of immunofluorescence detection of the relative expression of β -catenin in the nucleus and cytoplasm of different treatment groups.
FIG. 25 is a graph showing the results of protein expression levels of TCF4, c-myc, cyclD 1 and MMP 2.
Fig. 26 is a graph showing the results of in vivo experiments.
FIG. 27 is a graph showing the results of measuring the expression levels of TIMP3, SMAD7, p-AKT, c-Myc, and cyclinD 1.
FIG. 28 is a graph of the results of immunohistochemical staining.
FIG. 29 is a schematic representation of the action of CircSH3GL3 on ceRNA.
Detailed Description
The present invention will be further described with reference to specific embodiments, but the scope of the present invention is not limited thereto, and any person skilled in the art, who is within the scope of the present invention, should make equivalent substitutions or modifications according to the technical scheme of the present invention and the inventive concept thereof, and should be covered by the scope of the present invention.
Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
Experimental materials
Reverse transcription kit for RNAse and circRNAII First Strand cDNA Synthesis Kit), quantitative PCR detection kit (A.sub.L.)>qPCR/>Green Master Mix), circ_0104727FISH probes, circRNAs primers, RNA lmmunoprecipitation kit kit were purchased from Gicemetery Biotechnology Inc. of Guangzhou. Actinomycin D was purchased from sigma corporation of America. RNA nucleoplasm isolation extraction kit was purchased from Ambion company. The CircSH3GL3 siRNA and validated clear overexpressing lentiviruses were constructed by the biosciences of geese, inc. The circ0104727 double luciferase reporter plasmid and the mutant plasmid combined with miR-21-5p are also constructed and synthesized by Shanghai Ji Ma gene Limited. Immunohistochemical detection kit, gDNA extraction kit was purchased from beijing solebao biotechnology limited.
H4, NHA cell lines were purchased from Beijing North nano-InnovaThe technical institute, U251, U87, LN229, A172, T98G were purchased from Shanghai cell biosciences, national academy of medical science. The above cell lines were cultured in 1640 or DMEM containing 10% fetal bovine serum (Gibco), 100U/ml penicillin and 0.1mg/ml streptomycin (Sangon biotech), 37℃and 5% CO 2 Culturing in a humidified atmosphere. All cell lines were tested as mycoplasma negative. Cell transfection was performed using Lipofectamine3000 (Invitrogen), and cells were collected for detection after 48-72 hours.
Example one, identification of the expression profile of circRNAG in GBM tissue and paracancerous Normal brain tissue
To explore the role of circRNA in GBM development, we analyzed 3 clinical GBM specimens and corresponding paired ribosomal RNA deletion total RNA of adjacent normal tissues using microarray chips and constructed a circRNA database.
3 cases of fresh primary glioblastoma tissue and paracancestral normal brain tissue specimens were collected from neurosurgical treatment of GBM patients. The corresponding "normal brain tissue" is taken after the "normal boundary" of the resected tumor is determined by the intraoperative quick frozen section. Each tissue was about 0.5 cm. Times.0.5 cm in size, washed with physiological saline and placed in a labeled cryopreservation tube. Rapidly placing into a liquid nitrogen tank, transferring to a laboratory, and freezing at-80 ℃. All specimens were diagnosed as primary glioblastoma after surgery, and paracancestral histopathology confirmed that no cancer cell invasion was seen. All patients were not treated with chemotherapy prior to surgery. All patients were informed consent and signed with the consent of the owner or family.
3 examples the circRNA expression profile was detected on GBM specimens by the chip Arraystar Human circRNA Array from Beijing Boao Biotechnology Co. In GBM tissues, 1812 expression-abnormal circRNAs were identified in total, of which 711 expression was up-regulated and 1101 circular expression was down-regulated (FIG. 1A) (fold change >5, p < 0.05). In these differentially expressed circrnas, most are less than 1000 nucleotides in length, with different circRNA length distributions (fig. 1B), as well as the genomic origins of these significantly expressed circrnas. qRT-PCR validated 20 most significantly different circrnas, including the first 10 significantly up-regulated and the first 10 most significantly down-regulated circrnas, based on the source of the circBase database and the criteria that the original detected signal value was greater than 200. The cluster heatmap in fig. 1C shows 20 up-and down-regulated circrnas. Only the circRNA0071539, circRNA0104727 and circRNA0104722 were consistent with the expression propensity of GBM chip assays as verified by qRT-PCR and sanger sequences (FIG. 2).
Based on the abundance of expression, we focused on down-regulating the most significant circRNA0104727. Meanwhile, we found that 4 out of 10 down-regulated circrnas were derived from the linear gene SH3GL3, which was associated with GBM progression, according to bioinformatic analysis. Thus, we selected circRNA0104727 (the remainder of the invention is referred to as circSH3GL 3) for further functional and molecular mechanism studies.
To further verify the down-regulation of circSH3GL3, we examined 52 different grades of glioma, of which the low grade (WHOI-II) was 15 and the high grade (WHO III-IV) was 37.
Clinical 52 glioma specimens of different pathological tissue types were derived from the biomedical specimen library of the department of neurosurgery of the Tianjin city, including 9 oligodendroglioma encryptions (WHO grade), 6 astrocytomas (WHO grade 2 and WHO grade 4), 5 anaplastic oligodendrogliomas (WHO grade III), 3 anaplastic astrocytomas (WHO grade III), 29 primary glioblastomas (WHO grade IV), all patients were presented with consent from either the individual or the family, and informed consent was signed.
The results show that the expression of circSH3GL3 in GBM is significantly down-regulated compared to low grade gliomas and normal controls, negatively correlated with WHO grade, and that high expression of circSH3GL3 suggests a good prognosis. Furthermore, the Real-timeepcr assay of the expression of circSH3GL3 in glioma cell lines revealed that, except for U251 cells, circSH3GL3 was significantly down-regulated in GBM cell lines compared to NHA cell lines (fig. 3).
Thus, we further selected U251 cells for the circSH3GL3 loss of function experiment, while LN229 and U87 cells were selected for the restoration of function experiment.
Example two, features of circSH3GL3
1. Stability of circSH3GL3
We assessed the exon structure of circSH3GL3, which is derived from exons 5 to 11 of the SH3GL3 gene on chromosome 15. We designed a specific primer (Divergent primers) across the circularization site to identify and specifically detect circSH3GL3 by PCR amplification and agarose gel electrophoresis in U251 cell cDNA and genomic gDNA.
The specific PCR primer is F:5'-GTGAAGACGACAGCTATTTA-3' (SEQ ID NO. 1); 5'-GACACAGTGTTCAGCATTCC-3' (SEQ ID NO. 2), the amplified fragment of hsa_circ_0104727 has a size of 192bp.
The electrophoresis results showed that the primers were amplified only in cDNA and not in gDNA, whereas the linear gene SH3GL3 was amplified in both cDNA and gDNA (FIG. 4), and further Sanger sequencing was performed by PCR products amplified from cDNA, and specific circularization sites are shown in FIG. 5. These results confirm that the circSH3GL3 is a closed circular RNA formed at posttranscriptional level by reverse cleavage, and that the dissimilarity primer (Divergent primers) can specifically amplify.
After RNase enzyme digestion treatment of U251 cell RNA, quantitative PCR was used to detect the expression of circSH3GL3 and its corresponding linear RNA molecule SH3GL3, respectively. The results showed that circSH3GL3 was indeed more resistant to digestion by the RNaseR enzyme than the linear mRNA, whereas SH3GL3, compared to the RNaseR (-) group, the expression level of the RNaseR (+) group was significantly reduced (fig. 6A). Further, the stability of circSH3GL3 was indirectly verified by treatment of U251 cells with actinomycin D, and qRT-PCR results showed that after 24h of treatment with actinomycin D, the circSH3GL3 showed significant degradation compared to the linear RNA molecule SH3GL3 (FIG. 6B). As a result, it was confirmed that the circSH3GL3 molecule was more stable than the linear SH3GL3 molecule.
2. Subcellular localization of circSH3GL3
Subcellular localization of the circRNA molecule is closely related to its diverse biological functions. The circRNAs that are predominantly located in the cytoplasm act primarily through competing ceRNA mechanisms, whereas the circRNAs that are located in the nucleus act primarily through binding to RNA-binding proteins to regulate downstream target gene transcription and splicing.
We first extracted the nuclear and cytoplasmic RNAs of U251 cells using RNA nucleoplasm isolation experiments, respectively, and after reverse transcription of equal volumes of RNA, the intracellular distribution of circSH3GL3 was detected by quantitative PCR, and GAPDH and U6mRNA distribution in the nucleus and cytoplasm served as controls, showing that circSH3GL3 was mainly located in the cytoplasm of glioma cells (fig. 7A).
We then applied Fluorescence In Situ Hybridization (FISH) to further define the cell localization of circTOP 2A. FISH in situ hybridization probe sequence: hsa_circ_0104727 (5 ', 3' cy3 Labeled): TTCACTAAATAGCTGTCGTCTTCA (SEQ ID NO. 3). The single-stranded DNA probe specifically corresponding to the cleavage site of circSH3GL3 carries Cy 3-labeled red fluorescence, and the result observed by a laser confocal microscope is consistent with the result of RNA nucleoplasm separation experiment, and the circSH3GL3 is mainly located in cytoplasm (FIG. 7B).
The cytoplasmic localization of the circSH3GL3 is definitely established as a theoretical basis for the competitive miRNA binding effect by two methods.
Example three, high expression of circSH3GL3 significantly inhibited glioma cell proliferation and invasion
The role of circSH3GL3 in glioma progression was evaluated by gain-of-function and loss-of-function assays.
Based on the expression of circSHGL3 in glioma cell lines, circSH3GL3 was overexpressed in LN229 and U87 cells (circSH 3GL3 wild-type expression plasmid lentivirus, work done by the guangzhou gemini biosciences company for sequencing identification, recombinant lentiviral vector packaging, titer assay, expression validation, etc., contract No. GS200413-CZQ 034), and expression of circSH3GL3 knocked down in U251 cells.
qRT-PCR validated overexpression and knockdown efficiency of circSH3GL3 and indicated that transfection had no effect on the parental SH3GL3 gene (fig. 8A-B).
CCK8, edu and Transwell experiments show that compared with a vector group, the overexpression of the circSH3GL3 can remarkably inhibit proliferation and invasion capacity of tumor cells. Whereas si-circSH3GL 3-mediated inhibition of circSH3GL3 may significantly promote cell growth and invasiveness (fig. 9-11).
Example four competitive binding of CircSH3GL3 to miR-21-5p
The above results indicate that circSH3GL3 is mainly located in the cytoplasm, and that circSH3GL3 may exert an anti-tumor gene effect in GBM through competitive binding with miRNA in a ceRNA mechanism.
To identify downstream mirnas of circSH3GL3, we performed biotinylated circSH3GL3 probe RNA pull down experiments and miRNA high throughput sequencing of the enriched RNAs. Sequence results showed that 20 miRNAs were enriched. Based on the enrichment and Fold change > 2, qRT-PCR further validated 7 miRNAs, including has-miR-1-3p, has-miR-1246, has-miR-615-3p, has-miR-21-5p, hsa-miR-125b-1-3p, hsa-miR-4787-3p and hsa-miR-191-3p. Wherein, the specific enrichment of miR-1-3p, miR-21-5p and miR-615-3p is significantly higher than that of NC group, as shown in FIG. 12A.
Furthermore, in combination with our previous miRNA chip analysis of 3 pairs of GBM and adjacent non-tumor tissues, miR-21-5p is one of the most upregulated mirnas, abundant in GBM (fig. 12B). Thus, we selected miR-21-5p for further validation. miR-21-5p contains a putative targeting site for the circSH3GL3 region, as shown in FIG. 12C.
To verify the binding capacity of mirnas to circSH3GL3, we constructed a circSH3GL3 luciferase reporter plasmid system. The miR-21-5p seed sequences combined with TIMP3 and SMAD 7' UTR regions are predicted by using target gene prediction websites, mutant (MT) and Wild (WT) of the specific binding regions are respectively constructed on a luciferase reporter gene plasmid vector pmirGLO, and a plasmid vector map is shown in figure 13. The construction process is synthesized by Shanghai Ji Ma gene limited company, and the experimental method refers to the publication of the subject group: jikui Sun; jinhuan Wang; meng Li; shengjie Li; hanyun Li; yan Lu; feng Li; tao Xin; feng Jin; circTOP2A functions as a ceRNA to promote glioma progression by upregulating RPN2, cancer Science,2023,114 (2): 490-503.
MiR-21-5p mimic was co-transfected with the circSH3GL3 luciferase reporter gene into LN229 and U87 cells. The results demonstrate that miR-21-5p is able to significantly reduce the luciferase activity of the circSH3GL3-WT compared to the NC group, whereas there is no difference in the luciferase activity of the circSH3GGL3-MUT group (FIG. 14).
Then, the use of biotin labeled miR-21-5p pull down experiments demonstrated that the circSH3GL3 was significantly enriched in the miR-21-5p capture fraction compared to the negative control (FIG. 15).
In addition, further EDU and CCK8 functional experiments demonstrated that overexpression of miR-21-5p promoted cell proliferation, while overexpression of circSH3GL3 reversed miR-21-5p mimic-mediated proliferation promotion (FIG. 16).
These results indicate that circSH3GL3 competitively binds miR-21-5p and participates in glioma malignancy progression.
Example five, circSH3GL3 Regulation of TIMP3 and SMAD7 by competitive binding to miR-21-5p targeting
The research at present shows that miR-21-5p serves as a star molecule, and plays an important role in the occurrence and development of glioma by inhibiting various anticancer genes. Therefore, we hypothesize that circSH3GL3 inhibits tumor progression by protecting the miR-21-5p direct target gene. RNA-seq analysis after increasing the expression of circSH3GL3 revealed that 293 Different Expressed Genes (DEGs) were up-regulated (fold > 1.5) and 254 DEGs were down-regulated (fold > 0.5) in U87-circSH3GL3 cells compared to U87-Vector cells (FIG. 17). Applying up-regulated deg together with the miRanda database to predict potential targets for miR-21-5p we obtained 10 overlapping genes including TIMP3, SMAD7, TRIM2, ABCA1, FMN1, RAB27B, SEMA5A, SAMD, CYBRD1, CREB5. Finally TIMP3, SMAD7, FMN1 and CREB5 were selected for qRT-PCR validation, and the detailed screening flow chart is shown in FIG. 17.
qRT-PCR results showed that upregulation of circSH3GL3 could significantly increase mRNA levels of TIMP3 and SMAD7 without significant effect on mRNA levels of FMN1 and CREB5 (fig. 18).
Combining with a plurality of target gene prediction software such as ENCORI online database, PITA, picTar, microT, targetscan and the like, TIMP3 and SMAD7 are direct targets of miR-21-5p. MiR-21-5p seed sequences matched to the 3' UTR of TIMP3 and PDCD4 genes are shown in FIG. 19.
To determine whether circSH3GL3 could regulate the downstream genes TIMP3 and SMAD7, western blot detection was first performed, showing that upregulation of circSH3GL3 could significantly increase TIMP3 and SMAD7 protein levels, whereas miR-21-5p mimc partially reversed this effect (fig. 20A). Next, it was further confirmed whether TIMP3 and SMAD7 were direct targets for miR-21-5p, and western blot and dual luciferase reporter plasmid assays were performed. As a result, it was found that TIMP3 and SMAD7 proteins were significantly up-regulated after knockdown of miR-21-5p expression in LN229 and U87 cells (20B).
Furthermore, luciferase reporter assays demonstrated that downregulation of miR-21-5p resulted in a significant increase in pmirGLO-TIMP3-WT and pmirGLO-SMAD7-WT group luciferase activity, whereas pmirGLO-TIMP3-MT and pmirGLO-SMAD7-MT group luciferase activity did not change (FIG. 21), suggesting that miR-21-5p regulates TIMP3 and SMAD7 expression by direct binding to the 3' UTR of TIMP3 and SMAD 7. Finally, luciferase reporter assays showed that TIMP3 and SMAD7 wild-type significantly increased luciferase activity upon stable upregulation of circSH3GL3 expression compared to the mutated luciferase reporter (fig. 21), again confirming the regulatory effect of circSH3GL3 on miR-21-5p.
Example six, circSH3GL3 regulates PI3K/AKT and Wnt/beta-catenin signaling pathway through TIMP3 and SMAD7, respectively
Based on the mRNA sequences of U87 cells that were previously overexpressed by circSH3GL3, bioinformatic analysis showed various signaling pathway enrichment, including PI3K/AKT and Wnt/β -catenin signaling pathways, which are two major targets for GBM drug design. Further searching the literature in the Pubmed database, there is increasing evidence that TIMP3 can significantly inhibit the PI3K/AKT signaling pathway, while SMAD7 is an inhibitor of the Wnt/β -catenin signaling pathway. One glioma study reported that exosome-mediated MIF further activated PI3K/AKT signaling by down-regulating TIMP3, thereby promoting glioma TMZ resistance.
Therefore, we next examined whether circSH3GL3 regulates PI3K/AKT and Wnt/β -catenin signaling pathways by targeting TIMP3 and SMAD7, respectively. Western blot analysis showed that the overexpression of circSH3GL3 significantly inhibited p-PI3K, P-AKT and expression, with no effect on the total expression levels of PI3K and AKT (FIG. 22), whereas in LN229 and U87 cells that stably overexpressed circSH3GL3, siRNA-mediated TIMP3 inhibition could partially reverse the circSH3GL 3-mediated inhibition of PI3K/AKT pathway, as shown in FIG. 22.
The effects of the targeting SMAD7 on Wnt/β -catenin pathway were analyzed using TOP/FOP luciferase reporter assays (specific methods of experiments refer to the subject group publication: ma Q, li B, wang C, mo L, zhang X, tang F, wang Q, yan X, yano X et al: RPN2 is targeted by miR-181C and mediates glioma progression and temozolomide sensitivity via the Wnt/beta-catenin signaling pathway. Cell gap & disease 2020,11 (10): 890.), immunofluorescence assays of western blot and β -catenin. TOP/FOP luciferase reporter plasmid experiments demonstrated that the luciferase activity of the TOP plasmid group was significantly reduced by lentivirus-mediated circSH3GL3. In cell lines U251 and LN229, which stably knockdown the expression of circTOP2A, simultaneous knockdown of SMAD7 expression was able to reverse to some extent the reduction in luciferase activity mediated by circSH3GL3 (FIG. 23).
Western blot experimental results of important factors downstream of wnt signal transduction paths prove that: the expression of TCF4, c-myc, cyclinD1 and MMP2 was significantly inhibited by circSH3GL3, and likewise, expression levels of TCF4, c-myc, cyclinD1 were significantly up-regulated after simultaneous knockdown of SMAD7 expression (fig. 24). In addition, the expression change condition of the wnt pathway core factor beta-catenin in different treatment groups is detected through immunofluorescence analysis, and the result shows that after the circumsh 3GL3 is over-expressed, the level of the beta-catenin in the cell nucleus is obviously reduced, and the beta-catenin transcriptional activity mediated by the circumsh 3GL3 is reversed by knocking down SMAD7 (figure 25).
Example seven, effect of circSH3GL3 on glioma in vivo growth
To study the effect of circSH3GL3 on glioma growth, stereotactic in situ injection was 5×10 5 U87 cells marked by luciferase and stably over-expressing circSH3GL3 (Lv-circSH 3GL 3) or Lv-miR-21-5p are used for constructing a nude mouse intracranial model. Tumor progression was tracked by in vivo bioluminescence. The experiments were divided into three groups: lv-NC, lv-circSH3GL3, lv-circSH3GL3+LV-miR-21-5p group.
The volume of xenograft tumor formed by Lv-circSH3GL 3U 87 cells was significantly smaller than that of the control group (Lv-NC) (FIG. 26A), and the Kaplan-Meier analysis result showed that the survival period of the Lv-circSH3GL3 group was significantly prolonged (FIG. 26B).
The western blot results show that: protein levels of TIMP3, SMAD7 were significantly increased in LV-circSH3GL3 group and expression of p-AKT, c-Myc, cyclinD1 was significantly decreased (FIG. 27). Immunohistochemical staining showed increased expression of TIMP3 and SMAD7 in the Lv-circSH3GL3 group, consistent with western blot results (fig. 28). However, the results of the Lv-circSH3GL3+LV-miR-21-5p group suggest that: restoration of miR-21-5p expression to a certain extent reversed the upregulation of TIMP3 and SMAD7 by circSH3GL3 and the inhibition of PI3K/AKT and wnt/beta-catenin signaling pathways (FIG. 29), with consistent in vivo and in vitro results.
The foregoing is a further detailed description of the invention in connection with the preferred embodiments, and it is not intended that the invention be limited to the specific embodiments described. It will be apparent to those skilled in the art that several simple deductions or substitutions may be made without departing from the spirit of the invention, and these should be considered to be within the scope of the invention.
Claims (10)
- Application of hsa_circ_0104727 in regulation of glioma occurrence;more specifically, the hsa_circ_0104727 as ceRNA modulates glioma occurrence by competitive binding to miRNA-21-5 p;preferably, the glioma comprises an oligodendroglioma, an astrocytoma, a modified astrocytoma or a glioblastoma.
- Use of a miRNA-circRNA-TIMP3 or miRNA-circRNA-SMAD7 regulatory module for modulating glioma occurrence, wherein the circRNA is hsa_circ_0104727 and the miRNA is miR-21-5p;preferably, the glioma comprises an oligodendroglioma, an astrocytoma, a modified astrocytoma or a glioblastoma;preferably, the circRNA module in the regulation module eliminates the inhibition effect of the miRNA module on the TIMP3 module or SMAD7 module, thereby regulating the occurrence of glioma;more preferably, the TIMP3 inhibits the PI3K/AKT signaling pathway;more preferably, the SMAD7 inhibits the Wnt/β -catenin signaling pathway.
- 3. Use of a reagent for detecting hsa_circ_0104727 expression level in the preparation of a product having any one of the following functions:1) Diagnosing glioblastoma, and diagnosing the glioblastoma,2) The glioma is classified into a grade and a grade,3) Predicting prognosis of glioma patients;preferably, the glioblastoma is one of gliomas;preferably, the grading is to identify the glioma patient as a low grade glioma or a high grade glioma;preferably, the glioma comprises a WHO 1-4 grade, in particular, WHO 1-2 grade is a low grade glioma and WHO 3-4 is a high grade glioma;preferably, the glioma comprises an oligodendroglioma, an astrocytoma, a modified astrocytoma or a glioblastoma.
- 4. The use according to claim 3, wherein the reagent comprises a reagent used in the following method for detecting hsa_circ_0104727 expression: detection method based on PCR principle, southern hybridization method, northern hybridization method, dot hybridization method, fluorescence in situ hybridization method, DNA microarray method, ASO method, high throughput sequencing platform method;specifically, the detection method based on the PCR principle comprises variable temperature amplification and constant temperature amplification;specifically, the reagent is a primer pair, probe or antisense nucleotide that specifically binds to hsa_circ_ 0104727;further, the reagent further comprises a detectable label;further, the detectable label includes a radioisotope, a nucleotide chromophore, an enzyme, a substrate, a fluorescent molecule, a chemiluminescent moiety, a magnetic particle, a bioluminescent moiety.
- 5. A composition for treating glioma, said composition comprising any one or more of the following:1) hsa_circ_0104727 and/or hsa_circ_0104727 precursors,2) A polynucleotide which is transcribed to form hsa_circ_0104727,3) A delivery vehicle comprising 1) or 2) of,4) An agent for promoting hsa_circ_0104727 expression,5) A molecular pathway inhibitor, the molecular pathway comprising a PI3K/AKT signaling pathway and a Wnt/β -catenin signaling pathway;preferably, the composition contains a molecular pathway inhibitor;preferably, a pharmaceutically acceptable solid/liquid excipient is also included in the composition;preferably, the pharmaceutically acceptable solid/liquid excipients include binders, fillers, lubricants and disintegrants.
- 6. The composition of claim 5, wherein the delivery vehicle comprises an exosome, a viral vector, a lipid nanoparticle, a polymeric nanocarrier, an inorganic nanocarrier, or a protein carrier;preferably, the viral vector comprises a lentiviral vector, an adenoviral vector, an adeno-associated viral vector.
- Use of hsa_circ_0104727 or a composition according to claim 5 for the manufacture of a medicament for the treatment of glioma;preferably, the glioma comprises a WHO 1-4 grade glioma;preferably, the glioma comprises an oligodendroglioma, an astrocytoma, a modified astrocytoma or a glioblastoma;preferably, the glioma is glioblastoma.
- 8. A method of inhibiting glioma cell proliferation and invasion, the method comprising increasing the expression level of hsa_circ_0104727 in a target cell;preferably, the method is non-therapeutic;preferably, the method is performed in vitro.
- 9. A system having a judging means for giving any one of the following results by the expression level of hsa_circ_ 0104727:1) Whether the subject has glioblastoma,2) Glioma typing of the subject,3) Prognosis of glioma patients.
- 10. The system of claim 9, further comprising one or more of a detection device, an input device, an output device, and a communication device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311801007.9A CN117721204B (en) | 2023-12-26 | 2023-12-26 | CeRNA regulation mechanism of circ0104727 and application of ceRNA regulation mechanism in glioma |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311801007.9A CN117721204B (en) | 2023-12-26 | 2023-12-26 | CeRNA regulation mechanism of circ0104727 and application of ceRNA regulation mechanism in glioma |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117721204A true CN117721204A (en) | 2024-03-19 |
CN117721204B CN117721204B (en) | 2024-08-16 |
Family
ID=90203373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311801007.9A Active CN117721204B (en) | 2023-12-26 | 2023-12-26 | CeRNA regulation mechanism of circ0104727 and application of ceRNA regulation mechanism in glioma |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117721204B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117959448A (en) * | 2024-04-01 | 2024-05-03 | 呈诺再生医学科技(北京)有限公司 | New use of annular RNA CIRCTRIM2 expression promoter in diagnosis and treatment of liver cancer |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160060704A1 (en) * | 2013-04-05 | 2016-03-03 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Diagnosis of Glioblastoma or a Subtype Thereof |
CN109609651A (en) * | 2019-01-31 | 2019-04-12 | 山东大学齐鲁医院 | A kind of molecular marker of diagnosis and treatment glioma and its application |
CN115807082A (en) * | 2022-07-21 | 2023-03-17 | 山东第一医科大学第一附属医院(山东省千佛山医院) | Use of lncRNA LINREP for diagnosis, prognosis and treatment of glioma |
CN116287249A (en) * | 2023-02-14 | 2023-06-23 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | Hepatocellular carcinoma diagnosis and prognosis marker and application thereof |
-
2023
- 2023-12-26 CN CN202311801007.9A patent/CN117721204B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160060704A1 (en) * | 2013-04-05 | 2016-03-03 | The Wistar Institute Of Anatomy And Biology | Methods and Compositions for Diagnosis of Glioblastoma or a Subtype Thereof |
CN109609651A (en) * | 2019-01-31 | 2019-04-12 | 山东大学齐鲁医院 | A kind of molecular marker of diagnosis and treatment glioma and its application |
CN115807082A (en) * | 2022-07-21 | 2023-03-17 | 山东第一医科大学第一附属医院(山东省千佛山医院) | Use of lncRNA LINREP for diagnosis, prognosis and treatment of glioma |
CN116287249A (en) * | 2023-02-14 | 2023-06-23 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | Hepatocellular carcinoma diagnosis and prognosis marker and application thereof |
Non-Patent Citations (3)
Title |
---|
RYBAK ET AL.: "hsa_circ_0104727", 《CIRCBASE》, 31 December 2015 (2015-12-31) * |
ZHI NIE ET AL.: "SH3GL3 acts as a novel tumor suppressor in glioblastoma tumor igenesis by inhibiting STAT3 signaling", 《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》, vol. 544, 29 January 2021 (2021-01-29) * |
尚超等: "SH3GL2基因在人脑胶质瘤中表达的研究", 《解剖科学进展》, vol. 16, no. 2, 31 March 2010 (2010-03-31), pages 128 - 130 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117959448A (en) * | 2024-04-01 | 2024-05-03 | 呈诺再生医学科技(北京)有限公司 | New use of annular RNA CIRCTRIM2 expression promoter in diagnosis and treatment of liver cancer |
CN117959448B (en) * | 2024-04-01 | 2024-06-11 | 呈诺再生医学科技(北京)有限公司 | New use of annular RNA CIRCTRIM2 expression promoter in diagnosis and treatment of liver cancer |
Also Published As
Publication number | Publication date |
---|---|
CN117721204B (en) | 2024-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhuo et al. | Long noncoding RNA GMAN, up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of ephrin A1 by competitively binding GMAN-AS | |
US9914977B2 (en) | Individualized cancer therapy | |
US9062351B2 (en) | Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine | |
CN107267625B (en) | Application of lncRNA as biomarker in liver cancer diagnosis and treatment | |
JP5931897B2 (en) | Materials and methods associated with microRNA-21, mismatch repair and colorectal cancer | |
JP2012500389A (en) | MicroRNA-based compositions and methods for diagnosis, prognosis and treatment of multiple myeloma | |
EP2622105A2 (en) | Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease | |
US9040497B2 (en) | Treatment and diagnosis of colon cancer | |
CN117721204B (en) | CeRNA regulation mechanism of circ0104727 and application of ceRNA regulation mechanism in glioma | |
JP2017006137A (en) | miRNA USEFUL TO REDUCE LUNG CANCER TUMORIGENESIS AND CHEMOTHERAPY RESISTANCE AND RELATED COMPOSITION AND METHOD | |
CN113201591B (en) | Application of long-chain non-coding RNA and inhibitor thereof in preventing and treating breast cancer | |
CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
US8841269B2 (en) | Polynucleotides for use in treating and diagnosing cancers | |
US20140228236A1 (en) | Biomarkers, methods, and compositions for inhibiting a multi-cancer mesenchymal transition mechanism | |
CN113234815A (en) | Application of lncRNA molecule in GBM | |
CN107227362B (en) | Gene related to liver cancer and application thereof | |
US20230250478A1 (en) | Diagnosis and treatment of chronic diabetic complications using long noncoding rnas as targets | |
CN107184983B (en) | Diagnosis and treatment target for lung adenocarcinoma | |
CN111534587A (en) | Molecular marker 5-tRF-His, breast cancer detection kit and application thereof | |
CN105861736B (en) | Application of miRNA in endometrial cancer diagnosis and treatment | |
US10865415B2 (en) | Prevention, diagnosis and treatment of cancer overexpressing GPR160 | |
US20130131148A1 (en) | Micro-rna for cancer diagnosis, prognosis and therapy | |
US20200399710A1 (en) | Method of identifying tumor specific macromolecular isoforms | |
JP2021075473A (en) | Agents for preventing and/or treating mesothelioma | |
CN116440152A (en) | Application of WTAP inhibitor in preparation of medicine for treating atopic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |